Abstract: The invention relates to liposomes containing nanoparticles, wherein the nanoparticles are selected from magnetic, zparamagnetic, superparamagnetic and/or fluorescent and/or functionalized nanoparticles, and the liposomal sleeve contains lipid-derivatized bisphosphonic acid. The liposomes are suitable for preparing a solution for the diagnosis of pathological tissue degeneration or conversion processes on the bone and in the bone marrow, in particular for the treatment and diagnosis of bone tumors and bone metastases and disorders in the bone marrow (proliferative diseases of the blood-producing and lymphoreticular system).

Abstract: The present invention relates to a continuous two-phase hydroformylation process for the production of aldehydes from olefins by means of carbon monoxide, hydrogen and a transition metal catalyst in a reaction zone, the transition metal being in the form of a water-soluble catalyst complex, wherein the process comprising the following steps once or several times: a) hydroformylating by reacting the olefins, carbon monoxide and hydrogen over a water-soluble transition metal catalyst comprising water-soluble organophosphorus ligands in the reaction zone; b) reducing the concentration of the olefins in the reaction zone by reducing the olefin feed to the reaction zone and withdrawing at least a portion of the catalyst solution from the reaction system, wherein the catalyst solution withdrawal and olefin concentration reduction substeps may occur in this or reverse order, simultaneously or sequentially; c) feeding a solvent, a transition metal source and water-soluble organophosphorus ligands to the reaction sy

Abstract: The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

Abstract: The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

Abstract: The invention relates to a method for reprocessing a liquid product of a hydroformylation reaction, wherein the liquid phase produced in a release stage is supplied to a separating device from which a liquid flow containing rhodium is guided away via a filter, where solids thereby separated are taken out of the process and the filtrate obtained is guided back into the hydroformylation reaction.

Abstract: The invention relates to a method for reprocessing a liquid product of a hydroformylation reaction, wherein the liquid phase produced in a release stage is supplied to a separating device from which a liquid flow containing rhodium is guided away via a filter, where solids thereby separated are taken out of the process and the filtrate obtained is guided back into the hydroformylation reaction.

Abstract: A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.

Abstract: A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles, which is characterized in that the particles are provided with active substance(s) on at least part of their surface, is claimed. Modification of the magnetic particles is not absolutely required in this system. It can be incorporated both into aqueous and oily suspensions and into microemulsions, oil-in-water emulsions, water-in-oil emulsions and also water-in-oil-in-water emulsions.

Abstract: A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.

Abstract: An imaging auxiliary for medical imaging methods contains stabilizer-free superparamagnetic particles such as metal oxides and metals. Preferred are ?-Fe2O3, Fe3O4, MnFe2O4, NiFe2O4, and CoFe2O4 and their mixtures. The auxiliary can additionally contain biologically and pharmacologically active substances such as proteins, antibodies, peptides, or oligonucleotides. The superparamagnetic particles have a particle size of 1 nm to 500 nm. A tissue-specific substance in the form of diphosphonic acids and physiologically innocuous salts of diphosphonic acids can be added.

Abstract: The use of S-Clenbuterol for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of S-Clenbuterol leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage or destruction of nerve cells to be reduced and, in some cases, even prevented.

Abstract: A bisphosphonic acid of the general formula (I) wherein R1 is H, OH, C1-C6 alkyl C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 halogen alkyl X is a direct bond, alkylen group with 1 to 20 carbon atoms, (CH3)m—(OCR3HCH2)n—(O)o—, wherein R3 is H or CH3 and m is 0 or a number from 1 to 6, n is a number from 1 to 10, preferably 1 to 6, and o is 0 or 1, —(CR4HCH2O)p—, wherein R4 is H or CH3, p is a number from 1 to 10, preferably 1 to 6, (CH3)q—(OCR5HCH2)r—(O)s—(CH3)t—, wherein R5 is H or CH3 and q is 0 or a number from 1 to 6, r is a number from 1 to 10, preferably 1 to 6, and s is 0 or 1, and t is a number from 1 to 6, R2 is a group of the formula (II) as well as their physiologically compatible derivatives in particular salts and trimethyl silyl derivatives.

Abstract: A bisphosphonic acid of the general formula (I) wherein R1 is H, OH, C1-C6 alkyl C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 halogen alkyl X is a direct bond, alkylen group with 1 to 20 carbon atoms, (CH3)m—(OCR3HCH2)n—(O)o— wherein R3 is H or CH3 and m is 0 or a number from 1 to 6, n is a number from 1 to 10, preferably 1 to 6, and o is 0 or 1, ?—(CR4HCH2O)p— wherein R4 is H or CH3, p is a number from 1 to 10, preferably 1 to 6, ?(CH3)q—(OCR5HCH2)r—(O)s—(CH3)t—, wherein R5 is H or CH3 and q is 0 or a number from 1 to 6, r is a number from 1 to 10, preferably 1 to 6, and s is 0 or 1, and t is a number from 1 to 6, R2 is a group of the formula (II) as well as their physiologically compatible derivatives, in particular salts and trimethyl silyl derivatives.

Abstract: An aqueous catalyst solution comprising rhodium and an aqueous solution comprising sulfonated arylphosphines by reacting arylphosphines with oleum to form a sulfonation mixture, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble amine in a water-insoluble organic solvent, reacting the resulting water-immiscible organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solution of sulfonated arylphosphines of pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur dioxide is no longer liberated from the aqueous solution of sulfonated arylphosphines.

Abstract: A process for preparing sulfonated arylphosphines by reaction of arylphosphines with oleum, wherein, after reaction of the arylphosphines with oleum, the sulfonation mixture is firstly diluted with water, an inert gas stream is then passed through the diluted sulfonation mixture until SO2 is no longer liberated from the diluted sulfonation mixture and the latter is then worked up further in a customary manner and its use.

Abstract: A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles is characterized in that the particles are provided with active substance(s) on at least part of their surface. Modification of the magnetic particles is not absolutely required in this system. It can be incorporated both into aqueous and oily suspensions and into microemulsions, oil-in-water emulsions, water-in-oil emulsions and also water-in-oil-in-water emulsions.

Abstract: In a method for preparing 1-hydroxy-1,1-diphosphonic acid compounds of the general formula I and/or of their pharmacologically compatible salts a compound of the formula II is reacted with a compound P(OSiR53)3-pR6p and the reaction product is hydrolyzed.

Abstract: In a system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status—two components are provided: a medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.

Abstract: A process for preparing sulfonated arylphosphines by reaction of arylphosphines with oleum, wherein, after reaction of the arylphosphines with oleum, the sulfonation mixture is firstly diluted with water, an inert gas stream is then passed through the diluted sulfonation mixture until SO2 is no longer liberated from the diluted sulfonation mixture and the latter is then worked up further in a customary manner and its use.

Abstract: A process for preparing solutions of sulfonated arylphosphines comprising reacting arylphosphines with oleum, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble organic solvent, reacting the organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solutin of sulfonated arylphosphines to a pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur is no longer liberated from the aqueous solution of sulfonated arylphosphines.